Charles Schwab Investment Management Inc. Has $2.41 Million Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Charles Schwab Investment Management Inc. raised its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 36.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 122,019 shares of the company’s stock after acquiring an additional 32,393 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Kiniksa Pharmaceuticals were worth $2,414,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of KNSA. Quarry LP acquired a new position in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth about $50,000. China Universal Asset Management Co. Ltd. boosted its stake in Kiniksa Pharmaceuticals by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock worth $174,000 after acquiring an additional 1,004 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Kiniksa Pharmaceuticals during the third quarter valued at approximately $189,000. Y Intercept Hong Kong Ltd bought a new stake in Kiniksa Pharmaceuticals in the fourth quarter valued at approximately $258,000. Finally, New York State Common Retirement Fund increased its stake in Kiniksa Pharmaceuticals by 12.4% in the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company’s stock valued at $302,000 after purchasing an additional 1,680 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, COO Eben Tessari sold 14,000 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $19.57, for a total value of $273,980.00. Following the completion of the transaction, the chief operating officer now owns 81,975 shares of the company’s stock, valued at approximately $1,604,250.75. This trade represents a 14.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 8,879 shares of the business’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total transaction of $205,104.90. Following the sale, the chief financial officer now directly owns 23,382 shares in the company, valued at $540,124.20. This trade represents a 27.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 93,766 shares of company stock valued at $2,011,735 over the last three months. Company insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Stock Down 1.2 %

Kiniksa Pharmaceuticals stock opened at $23.09 on Friday. The company has a 50 day moving average of $20.77 and a 200-day moving average of $22.00. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $16.56 and a twelve month high of $28.15. The stock has a market capitalization of $1.68 billion, a PE ratio of -164.92 and a beta of 0.48.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The company had revenue of $122.50 million during the quarter, compared to analyst estimates of $123.42 million. During the same period in the previous year, the company posted $0.35 earnings per share. Kiniksa Pharmaceuticals’s revenue for the quarter was up 46.9% on a year-over-year basis. Equities analysts anticipate that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on KNSA shares. Wedbush reissued an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a research report on Tuesday, February 25th. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They set a “buy” rating and a $40.00 target price on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals presently has an average rating of “Buy” and an average price target of $37.17.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.